|Bid||1.0100 x 4000|
|Ask||1.0200 x 4000|
|Day's range||0.9938 - 1.1000|
|52-week range||0.9938 - 4.6800|
|Beta (5Y monthly)||0.98|
|PE ratio (TTM)||N/A|
|Earnings date||06 Nov 2023 - 10 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.30|
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Key Insights Institutions' substantial holdings in Heron Therapeutics implies that they have significant influence over...
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -58.82% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?